Telix Pharmaceuticals (OTCMKTS:TLPPF) Trading Down 1.4% – What’s Next?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) fell 1.4% on Wednesday . The stock traded as low as $7.68 and last traded at $7.68. 6,878 shares were traded during trading, an increase of 25% from the average session volume of 5,484 shares. The stock had previously closed at $7.79.

Telix Pharmaceuticals Stock Down 1.4%

The company has a fifty day moving average of $9.47 and a 200 day moving average of $11.47.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.